Recently published research shows that the use of cannabis is not independently linked to a loss of motivation among adolescents. The study was conducted over a two-year period by a team of researchers associated with the Florida International University. Study results were published in the Journal of the “International Neuropsychological Society.”

The study’s authors note that a decrease in motivation is commonly mentioned as a consequence of marijuana. However, prior studies have largely centered on adults and have yielded different results. For their study, the researchers recruited more than 400 subjects aged between 14 and 17. Each subject had to complete a quintet of biannual assessments during the study.

The investigators evaluated the motivation of each participant by using two self-reported questionnaires: the Motivation and Engagement Scale and the Apathy Evaluation Scale, which comprise of subscales that measure the value, self-effectiveness, planning, persistence and disengagement that the subjects place on school. In addition, the investigators asked every participant about their use of tobacco, cannabis and alcohol during each evaluation and conducted an analysis of the data to model patterns of motivation and the use of marijuana over time.

The study’s raw results show that the use of marijuana grew considerably, as did the lack of engagement and motivation. The greater use of marijuana was linked to less valuing of school, lower planning and more disengagement. It should be noted, however, that once the data was controlled for variables including the effects of other factors such as depression, sex and age, as well as the participants’ reported use of tobacco and alcohol, the team discovered little evidence that the use of marijuana had an effect on motivation.

In their report, the study’s authors stated that their findings didn’t support a relationship between a decline in motivation and the use of marijuana over time. The researchers also noted that the study didn’t show a loss of motivation over time, even when respondents reported a considerable increase in the use of marijuana.

The researchers explained that the change in the use of marijuana didn’t forecast changes in motivation, despite the increase in the levels of marijuana use, which proposes that the use of marijuana may not cause a decline in motivation over time. The researchers also noted that future study will continue to examine these links longitudinally in order to determine if heavier levels of marijuana use leads to a decrease in motivation.

In a press release, NORML deputy director Paul Armentano stated that these findings served to destroy outdated stereotypes about marijuana.

It looks like the cannabis industry, including players such as Flora Growth Corp. (NASDAQ: FLGC) have one less myth to contend with, thanks to the research done by the Florida International University team.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at http://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

A new study suggests that the general public’s perception of the possible harms of psilocybin mushrooms doesn’t align with drug laws. The study found that magic mushrooms were considered to be less dangerous in comparison with tobacco, alcohol and other substances. The study was published in the “Journal of Psychopharmacology.”

The study’s author, professor Carl Roberts from the department of psychology at the University of Liverpool, stated that he was greatly interested in how substances affected an individual’s behavior as well as their brain. He explained that he had been following research on the therapeutic potential of psychedelic substances such as psilocybin, adding that he knew that the data on the actual harm of the use of psilocybin mushrooms proposed that the substance’s abuse potential and toxicity was low.  However, he continued, the substance was still classified as a Schedule 1 drug in the United States, which suggests that it is just as harmful as cocaine and heroin.

Roberts revealed that his interest in finding out the general public’s perception of harms around psilocybin mushrooms and whether they aligned with scientific evidence or the government’s legal classifications is what led to the study being conducted.

For their research, the researchers recruited more than 150 participants from different social media pages and websites that provide information on recreational drug use. Roughly 20% of them came from the United States while about one-half of the remaining number were from the United Kingdom. The remainder were from other countries in the European Union.

The researchers discovered that most participants considered psilocybin mushrooms to be relatively safe, in comparison with the other substances. This is despite the fact that psilocybin mushrooms are classified as a Class A substance in the U.K. and a Schedule I substance in the U.S.

The participants who had never used psilocybin listed it as the second-least dangerous substance while those who had used these mushrooms prior to the study listed it as the least dangerous substance from the list. The non-users listed marijuana as the least dangerous substance. Roberts explained that their findings proposed that the general perception of psilocybin mushroom harm aligned with scientific data on their toxicity and abuse potential as well as the relative harms of magic mushrooms that are scientifically recognized.

He notes though that the study had some limitations, including the potential of selection bias as it was an online survey style study.

That notwithstanding, the positive public perception of psilocybin means that when companies such as Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) bring to market medicines or products relating to psilocybin, the public reception is likely to be warm from the get-go.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Despite its youth and immaturity, America’s state-legal cannabis industry has been dubbed one of the fastest-growing sectors in the country. The sector has generated billions of dollars in revenue for businesses and provided jobs for hundreds of thousands of people. In addition, projections have the space pulling in $43 billion by 2025. Cannabis is a high-risk industry and potentially a high-reward industry, especially for companies that can weather the risks, and many businesses are looking to throw their hats into the ring.

Michigan, for instance, legalized recreational cannabis only one and a half years ago, and its large population coupled with favorable cannabis policies make it an increasingly attractive market. Since last April, Michigan’s recreational cannabis sales have exceeded $100 million, and cannabis sales are expected to surpass $1.2 billion this year. According to projections by the 2021 MJBizFactbook, recreational sales in Michigan are set to quadruple from around $500 million in 2020 to roughly $2 billion–$2.5 billion in 2025.

Presently, Michigan has an estimated 200 recreational cannabis stores, putting it at one dispensary for every 34,000 residents. According to Frank Colombo, the director of data analytics for Viridian Capital Advisors, the state has little market penetration and is still in a “process of consolidation.” As such, interested cannabis companies can pitch tent in Michigan’s recreational cannabis sector with relatively little competition, at least for the moment. In fact, a report that was recently released by the New York-based Cowen Group states that Michigan is home to one of the biggest cannabis markets in the country.

The state’s cannabis policies make its cannabis space enticing to businesses in the cannabis space. For starters, Michigan currently has unlimited licensing on a statewide basis, which has led to lower acquisition prices compared to states such as Illinois. This allows established businesses as well as new entrants to acquire other cannabis operators without having to break the bank. On the municipal level, however, the state has seen several municipalities opt out of launching legal markets. While more municipalities are expected to opt in over time, probably with licensing caps, limiting licenses will allow existing businesses to retain their market share and profitability for longer without having to contend with competition.

Thanks to an uptick in cultivation facilities, there are fewer cannabis flower shortages, and flower is more affordable than it was when Michigan first launched its recreational industry. Beginning Oct. 1, 2021, the state will also reduce its licensing fees from $25,000 to $7,500, which, coupled with cheaper cannabis flower, will reduce operational costs.

It goes without saying that cannabis companies such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) that have a presence in Michigan have contributed to making the industry successful.

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

A mandate from the Centers for Medicare and Medicaid Services directed that from Jan. 1, 2021, all hospitals in the United States provide pricing information online about their services and items. The objective of this mandate is to help inform patients about the cost of procedures and services before they receive them.

Researchers from Brigham and Women’s Hospital and Massachusetts Eye and Ear used this data to examine price variation and transparency for thyroid cancer treatment. They discovered that both price and transparency differed greatly, with the costs of various services having huge variations and only one-half of the cancer centers included in the study revealing negotiated prices.

The study’s results were reported in the “JAMA Network” journal.

Roy Xiao, an otolaryngology-head and neck surgery resident at the institution and the study’s corresponding author, stated that revealing negotiated prices was crucial in assisting patients in estimating the cost of care before treatment was administered. Xiao added that while the researchers expected some degree of variation based on prior research, the range they observed was astonishing.

The study centered on thyroid cancer because the treatment of this particular cancer is known to impose huge financial burdens on patients. Rates of bankruptcy are the highest for patients with thyroid cancer, in comparison to other patients who suffer from other types of cancer. The scientists distinguished price variation and availability for thyroid care in more than 50 NCI-designated centers (National Cancer Institute) in their study. Of this number, half revealed commercial payer-negotiated prices for any services or items.

The researchers observed extensive differences across centers, even after they normalized factors that affect the cost of delivery of care, disclosing that there was a 44-fold variation in the neck-computed tomography costs and a 70-fold variation in radioactive iodine treatment costs. They added that, on average, procedures such as a thyroid uptake scan and a fine needle aspirate biopsy differed by roughly 5-fold among the centers.

The researchers note that while the Centers for Medicare and Medicaid Services requires hospitals to reveal negotiated rates for physicians employed by the institution, physicians who practice at these hospitals are usually employed by associate physician organizations, which may explain why many centers don’t disclose surgeon professional fees for thyroid surgery. They also observe that their research was carried out shortly after these price-transparency requirements were implemented, which means that transparency and disclosure rates may increase as more centers comply with the mandate. The study’s senior author, Rosh K.V. Sethi, asserts that price transparency will help both physicians and patients understand differences in cost.

The disparities in the costs incurred by thyroid cancer patients make a strong case for personalizing treatment modalities in the way that is exemplified by what companies such as Predictive Oncology (NASDAQ: POAI) are doing since a customized protocol stands a higher chance of improving patient outcomes, thereby lowering costs incurred in the long term.

NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Lexaria just completed dosing for its second human clinical study, HYPER-H21-2
• The study sought to understand the human response to Lexaria’s DehydraTECH 2.0-enabled CBD
• The company also announced that its DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the United States
• Lexaria also expanded its intellectual property portfolio with the allowance of its second patent in Japan
• It also received US$3,817,643 from warrant exercises, proceeds from which will be used to advance the company’s research and development program and for its general corporate purposes

Lexaria Bioscience (NASDAQ: LEXX) has been making incredible strides in 2021 as it works towards achieving its business plan objectives. At the beginning of the year, the company set out to conduct three human clinical studies, two of which are underway at the time of this article.  Its most recent human clinical study, HYPER-H21-2, dosing was completed in July 2021 and was designed to understand better the human response to Lexaria’s DehydraTECH 2.0-enabled CBD (https://cnw.fm/Tzr2W). The company projects that preliminary results would be available for reporting either in September or earlier.

This second human clinical trial involved 16 human volunteers who previously dealt with hypertension or were mildly hypertensive at the time of the study. Each of the 16 participants received three different doses of 150 mg each of DehydraTECH(TM) 2.0-enabled CBD versus a placebo for a total dose of 450 mg. the study involved a 24-hr continuous ambulatory (portable) monitoring of vitals such as blood pressure and heart rate, while also taking into consideration evaluations of central arterial stiffness, physical activity as well as sleep quality.

Lexaria hopes to commence with the third and last human clinical hypertension study of 2021, HYPER-H21-3. It will offer updates in due course.

As the company celebrates the progress achieved through this second human clinical trial, Lexaria marked another massive milestone by increasing its market reach in the United States (“US’).  With partnerships with Cannadips, New World CBD, Impact Naturals and Amari, among others, Lexaria’s DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the US (https://cnw.fm/yg4Fv).

In an official statement from Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria, he noted that “Lexaria technology is enabling increased market share and sales growth for our continually growing list of corporate clients. We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come.”

Lexaria is a global leader in enhancing the overall speed and efficiency of orally-delivered fat-soluble active molecules and drugs. With its drug delivery technology and its advancing intellectual property (“IP”), the company is transforming existing consumer products and medications that may improve their availability and bioavailability. Its flagship technology, DehydraTECH(TM), improves how active pharmaceutical ingredients (“APIs”) enter the bloodstream, primarily by promoting healthier oral ingestion methods and increasing the effectiveness of the fat-soluble active molecules.

As of early July 2021, Lexaria had 20 patents falling under 13 different patent families. In July, it got its second patent in Japan titled “Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof.” This became the company’s 21st patent granted to the company and the 17th patent granted to its first patent family.

Also, in July, Lexaria received US$3,817,643 from warrant exercises. The company issued the warrants in relation to its January 2021 public underwritten offering. Under this offering, the shares and warrants issued were registered according to a Form S-1 Registration Statement. They were excised into 580,189 shares of voting common stock of the company at an exercise price of US$6.58 per share (https://cnw.fm/dmMfb).

Lexaria noted that all proceeds received from the warrant exercises would be used to continue advancing the company’s investigational research program and for general corporate purposes.

With these critical milestones achieved so far, Lexaria is confident that its business plan objectives, along with all its operations, are now all set and fully funded, well into the 2022.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

A recent study published in the “Consciousness and Cognition” journal has found that language produced while an individual is under the influence of LSD shows decreased semantic coherence and increased entropy levels. In layman’s terms, this means that people were more likely to move from one topic to another and have more disorganized speech while under the influence of LSD.

Entropy was developed by physicists to quantify lost energy in mechanical systems. However, researchers have found that this measure of randomness and uncertainty in a system can also be used to measure spontaneous activity in brain networks.

Study author Enzo Tagliazucchi, who is als the director of the Consciousness, Culture and Complexity Lab and a professor at the University of Buenos Aires, stated that a few years ago, it was proposed that the effects of psychedelic substances were brought about by increased disorganization of patterns of brain activity.  He noted that the hypothesis was strongly supported by neuroimaging experiments in people, which led to speculation that increased entropy levels could also have an effect on natural language production. This is what prompted the researchers to study whether psychedelic substances had a disorganizing effect on natural speech.

For their study, the researchers recruited 20 healthy participants who either received a dose of placebo or a dose of LSD before undergoing magnetoencephalography (“MEG”) and functional magnetic resonance imaging (“fMRI”) scans at a neuroimaging laboratory. Each participant had to visit the lab twice, with each visit being two weeks apart. In addition to this, each participant was interviewed by the researchers regarding their feelings and thoughts during the experience.

The researchers then used computer algorithms to conduct an analysis of the participant’s speech patterns, which led them to the discovery that in comparison to those under the influence of placebo, participants under the effects of LSD scored higher on speech disorganization. The researchers also found that while the latter group tended to use more words while under the influence of LSD, their vocabulary was relatively smaller.

In their report, the researchers note that the order of dosing was randomized, adding that the study had some limitations, including the fact that the participants could easily make out whether they had consumed the placebo or LSD. This, the researchers explained, changed the participants’ attitude toward the experiment. They note that subjects tend to speak more while under the influence of LSD in comparison with those under the effects of the placebo.

The diverse (both good and potentially adverse) effects of psychedelic compounds such as LSD may explain why sector players including Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) prefer to concentrate their R&D efforts on developing medicinal formulations to be administered under the watchful eye of trained medical professionals.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

• AnPac Bio-Medical Science Co. Ltd. is a biotechnology company focused on early cancer screening and detection
• The company aims to develop, distribute and deploy its Cancer Differentiation Analysis (“CDA”) technology to change the way people approach cancer screening
• CDA is powered by a database of over 200,000 samples and cases, providing a new way to approach disease and cancer screening
• The company’s management team comprises professionals in both the United States and China who are knowledgeable and well educated in cancer screening and detection
• The global cancer diagnostics market is expected to reach $249.6 billion by 2026

AnPac Bio-Medical Science Co. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection. The company develops, distributes and deploys accessible early disease detection devices with an aim of changing the way people approach cancer screening. AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance.

AnPac Bio-Medical has clinical laboratories in the United States and China, with 142 issued patents as of March 31, 2021. Its corporate headquarters is located in Shanghai, China, while its U.S. headquarters is situated in Philadelphia, Pennsylvania. The company operates two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States.

Cancer Differentiation Analysis (“CDA”)

Cancer Differentiation Analysis (“CDA”) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins to discover cancerous environments before the tumors even form.

Most liquid-based cancer screening and detection technologies focus on biochemical signals, like conventional biomarkers and genomic signals, such as ct-DNAs and CTCs (circulating tumor cells in the blood). These typically only determine whether or not cancer has occurred at a fixed point in time.

CDA technology combines an assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead-up to serious health conditions and cancer. It is also used to pinpoint where cancer is most likely located and predict where the risk is highest in the future – all through a standard blood test, at a competitive price point.

AnPac Bio-Medical’s CDA is powered by a database of over 200,000 samples and cases and serves as a new way to approach disease and cancer screening. The device uses an integrated system of sensors to detect several biophysical signals at the cellular, protein and molecular levels. CDA leverages a proprietary algorithm to synthesize the data, effectively generating a personalized risk assessment for evaluated patients.

Through CDA technology, AnPac Bio-Medical aims to address a number of goals, including:

• Innovate – AnPac Bio-Medical is an innovator in the cancer screening industry, with CDA research ongoing since 2008, and commercial operations beginning in 2015. AnPac considers itself a thought leader in developing multi-cancer screening.
• Detect – AnPac Bio-Medical detects early signals of threatening cancer and its location within the body.
• Identify – CDA identifies the risks of up to 26 different types of cancers with high sensitivity and specificity rates.
• Provide – The company’s platform provides multi-level, multi-parameter analysis using proprietary diagnostic algorithms, which results in accurate and easy-to-understand results.
• Proven – A fully operational analysis of over 200,000 test samples has been run to date. CDA technology has been shown to identify pre- and early-stage cancers in patients previously diagnosed as “cancer-free” through traditional methods.
• Biophysical Properties – CDA analyzes biophysical properties in human blood and the correlation between biophysical properties and cancer occurrence.

Market Outlook

AnPac Bio-Medical is exploring detection of other types of cancers leveraging its innovative CDA technology and multi-cancer screening and detection tests, which could open significant opportunities on the global cancer diagnostics market.

According to a report by Grand View Research, the cancer diagnostics market is expected to reach $249.6 billion worldwide by 2026 (https://ibn.fm/EMdoS). The market is expected to grow at a CAGR of 7% during the forecast period.

Management Team

Dr. Chris Yu is the Co-Founder and Chief Executive Officer of AnPac Bio-Medical. He has enjoyed a successful career as an innovator in life sciences, technology and engineering. Dr. Yu has worked for three U.S. Fortune 500 companies and is the first/principal inventor of over 300 patent applications spanning semiconductors, materials and life science. He has a proven history of developing cutting-edge products with long-term profit and sustainability. Dr. Yu was born to a medical doctor’s family and went to medical school. He later switched his major to physics and received his bachelor’s and master’s degrees in physics from the University of Missouri-Kansas City Campus and a doctoral degree in physics from Pennsylvania State University. Both of his dissertations addressed innovative detection techniques.

Dr. Herbert Yu is the Co-Founder and Chief Medical Officer of AnPac Bio-Medical. He is a renowned expert in molecular epidemiology, with training in medicine and chemical biochemistry. Dr. Yu has a 20-year career in leading-edge cancer research, including breakthrough work in areas of carcinogenic factors. He is a professor and research director at the University of Hawaii and an adjunct professor at Yale University. He received his bachelor’s degree in medicine from Shanghai First Medical College. Dr. Yu also received a science degree in epidemiology and a Ph.D. in clinical biochemistry from the University of Toronto.

Jingiu (Edward) Tang is the company’s Chief Financial Officer. He previously served as a global internal auditor at Natuzzi S.p.A. Mr. Tang also worked at Beijing Dongshen CPA and Shanghai De’an CPA, providing external audits, finance and tax advisory services across different industries and sectors. He is a Certified Public Accountant in Australia. Mr. Tang received his bachelor’s degree in accounting from Charles Sturt University in Australia, his MBA from Charles Sturt University, and his bachelor’s degree in law from Southwest University of Science and Technology in China.

Weidong Dai is the company’s China General Manager. He previously served as a general partner at Stirrfir Investment Management Co. Mr. Dai has also served as the chairman of RTS Management (Shanghai) Co., and as managing director of Hong Kong Pro-Health Technology Co. and Shanghai Pro-Health Medical Devices Co. He has published a number of medical research papers and research articles in professional journals. Mr. Dai was awarded the Hong Kong Industrial Award for a medical device that he led in research and development. He earned his bachelor’s degree in medicine from Anhui Medical University, a master’s degree in medicine from the Sun Yat-San University of Medicine, and an Advanced Certificate of the EMBA CEO Program from Fudan University, School of Economics.

For more information, visit the company’s website at www.AnPacBio.com.

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.